For example, the dual HER2 blockade with neoadjuvant trastuzumab, lapatinib and paclitaxel in patients with PAM50 HER2-enriched early BC demonstrated to induce low-proliferative Luminal A phenotype [71]. This evidence concerns the gene ERBB2 and breast cancer.